Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

LEAD-6 Study Shows Better Results With Liraglutide Than Exenatide In Controlling Blood Glucose In Type 2 Diabetes
The results of the LEAD-6 study are published in an article Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association meeting in New Orleans, USA. They indicate that taking liraglutide once a day is more efficient in controlling blood glucose in type 2 diabetes than the presently marketed treatment - two doses a day of exenatide.

Watson Pharmaceuticals Receives A Complete Response Letter For Its 24-Week Formulation Of TRELSTAR(R) (triptorelin Pamoate) NDA From US FDA
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative treatment of advanced prostate cancer. The TRELSTAR(R) NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies.
News of the day
Parents Ask Lawmakers To Keep Kids In Mind During Reform Debate
A group of 50 families will ask lawmakers this week to keep in mind 9 million uninsured children and many more who are underinsured when they undertake health reform this summer, the Cincinnati Enquirer reports. "Covering all children, and making sure they have access to the care they need regardless of their family"s financial situation or where they live, is an achievable first step toward covering all Americans," the CEO of the Children"s Hospital Association told the Enquirer.
Endocrinology

Brain-Scanning Process That Holds Promise For Epilepsy Treatments Developed By University Of Minnesota Researcher

University of Minnesota McKnight professor and Director of Center for Neuroengineering Bin He has developed a new technique that has led to preliminary successes in noninvasive imaging of seizure foci. He"s technique promises to play an important role in the treatment of epileptic seizures. Click here to view a video explaining the procedure. He"s research, called Functional Neuroimaging, has completed its first round of testing in epilepsy data collected at the Mayo Clinic. He"s medical device images the brain while epilepsy patients have a seizure and then allows surgeons to identify the network where the seizure is caused. Approximately one-third of people who suffer from epileptic seizures cannot be treated by medication, and this process could lead to further advancements in surgical treatment. He"s research is funded by the National Institutes of Health and the National Science Foundation. Patty Mattern University of Minnesota


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009